GlassScriptPhysician profile
Michael L Conley
NPI 1194105601
$4,957.57
in general payments reported to CMS, 2019-2025
25 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.73 · 2020: $26.70 · 2021: $1,011 · 2022: $923 · 2023: $1,835 · 2024: $290 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Travel and Lodging: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.60 |
| Travel and Lodging | $759.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,383.81 | 2021-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Glaxosmithkline, LLC. | $951.69 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $820.74 | 2023 | |
| Ethicon INC. | $443.05 | 2022-2025 | Monarch Platform |
| Astrazeneca Pharmaceuticals LP | $239.60 | 2019-2025 | Breztri, Tezspire, Symbicort |
| Genzyme Corporation | $157.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.23 | 2022-2024 | Ofev, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $117.57 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $114.80 | 2020-2024 | Glassia |
| Amgen INC. | $111.09 | 2023-2024 | Tezspire |
| Inogen, INC. | $83.68 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genentech USA, INC. | $64.12 | 2022-2023 | Xolair |
| Electromed, INC. | $57.61 | 2022-2023 | Smartvest |
| Covis Pharma Gmbh | $40.89 | 2022-2023 | |
| Baxter Healthcare | $38.29 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.95 | 2023 | |
| Grifols USA, LLC | $29.57 | 2022-2023 | Prolastin-C Liquid |
| Medtronic, INC. | $23.27 | 2025 | Bis |
| United Therapeutics Corporation | $22.22 | 2024 | Tyvaso |
| Chiesi USA, INC. | $21.49 | 2025 | Cleviprex |
| Ethicon US, LLC | $18.18 | 2022 | |
| Haemonetics Corporation | $17.27 | 2022 | |
| Philips North America LLC | $13.89 | 2023 | |
| Mylan Specialty L.P. | $13.15 | 2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.